We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Is raising HDL a futile strategy for atheroprotection?
- Authors
Joy, Tisha; Hegele, Robert A
- Abstract
The dramatic failure of clinical trials evaluating the cholesterol ester transfer protein inhibitor torcetrapib has led to considerable doubt about the value of raising high-density lipoprotein cholesterol (HDL-C) as a treatment for cardiovascular disease. These results have underscored the intricacy of HDL metabolism, with functional quality perhaps being a more important consideration than the circulating quantity of HDL. As a result, HDL-based therapeutics that maintain or enhance HDL functionality warrant closer investigation. In this article, we review the complexity of HDL metabolism, discuss clinical-trial data for HDL-raising agents, including possible reasons for the failure of torcetrapib, and consider the potential for future HDL-based therapies.
- Publication
Nature reviews. Drug discovery, 2008, Vol 7, Issue 2, p143
- ISSN
1474-1784
- Publication type
Journal Article
- DOI
10.1038/nrd2489